Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis”

3 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 3 of 3 results

Not applicableLooking for participantsNCT06173076
What this trial is testing

A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis

Who this might be right for
Autoimmune EncephalitisLeucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Shen Chun-Hong 60
Testing effectiveness (Phase 2)Ended earlyNCT04875975
What this trial is testing

Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Who this might be right for
Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
UCB Biopharma SRL 12
Large-scale testing (Phase 3)Active Not RecruitingNCT05503264
What this trial is testing

Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

Who this might be right for
NMDAR Autoimmune EncephalitisLGI1 Autoimmune Encephalitis
Hoffmann-La Roche 122